文献速递其他结缔组织病

特发性炎性肌病中抗Ro52抗体的临床意义:基于肌炎特异性抗体亚组的分析

Anti-Ro52 antibodies in idiopathic inflammatory myopathies: clinical significance across myositis-specific antibody-defined subgroups.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究纳入2002年4月至2023年4月中日友好医院治疗的2126例特发性炎性肌病(IIM)患者,分析抗Ro52抗体在不同肌炎特异性抗体(MSA)定义亚组中的频率、临床特征及预后价值。结果显示978例(46.0%)患者抗Ro52抗体阳性,在抗MDA5阳性皮肌炎(DM)和抗合成酶综合征(ASyS)中频率较高;在抗MDA5阳性DM中,抗Ro52抗体与间质性肺病(ILD)、快速进展型ILD及更差预后相关,且与抗SSA抗体共存时预后更差;在ASyS中与肺部受累相关但不影响预后;其他MSA亚组中临床意义有限。

要点

  • IIM患者中抗Ro52抗体阳性率达46.0%,为最常见的肌炎相关抗体。
  • 抗MDA5阳性DM中,抗Ro52抗体与ILD、快速进展型ILD及更差预后相关。
  • ASyS中抗Ro52抗体与肺部受累相关,但与预后无关。

核心结论

  • 抗Ro52抗体在IIM患者中高度流行,尤其在抗MDA5阳性DM和ASyS中。
  • 抗Ro52抗体检测可能有助于抗MDA5阳性DM和ASyS的风险分层与预后评估。

研究设计与样本

  • 该队列纳入2002年4月至2023年4月中日友好医院治疗的2126例IIM患者。
  • 在每个MSA定义亚组中评估抗Ro52抗体与临床特征及结局的关联。

主要发现

  • 978例(46.0%)患者抗Ro52抗体阳性。
  • 抗Ro52抗体在抗MDA5阳性DM和ASyS中频率显著高于其他IIM血清型。
  • 抗MDA5阳性DM中,抗Ro52抗体与ILD、快速进展型ILD及更差预后相关。
  • 抗MDA5阳性DM中,抗Ro52与抗SSA抗体共存进一步与更差预后相关。
  • ASyS中抗Ro52抗体与肺部受累相关但不与预后相关;其他MSA亚组中临床意义有限。

临床怎么用

  • 对IIM患者检测抗Ro52抗体,尤其在抗MDA5阳性DM和ASyS中用于风险分层。
  • 抗MDA5阳性DM中抗Ro52抗体阳性提示需关注ILD及快速进展型ILD风险。
  • 抗MDA5阳性DM中抗Ro52与抗SSA抗体共存提示预后更差,需加强评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to investigate the frequency, clinical characteristics, and prognostic value of anti-Ro52 antibodies in patients with idiopathic inflammatory myopathies (IIMs), especially in IIM subgroups with distinct myositis-specific antibodies (MSAs). METHODS: This cohort included 2126 patients with IIMs treated at the China-Japan Friendship Hospital between April 2002 and April 2023. Associations between clinical features and outcomes with anti-Ro52 antibodies were evaluated in each MSA-defined subgroup. RESULTS: In total, 978 (46.0%) patients presented with anti-Ro52 antibody positivity. Anti-Ro52 antibodies represented the most common myositis-associated antibody in IIM patients, with notably higher frequencies observed in patients with anti-melanoma differentiation-associated gene 5 (MDA5)+ DM and anti-synthetase syndrome (ASyS) compared with other IIM serotypes. In patients with anti-MDA5+ DM, anti-Ro52 antibodies were associated with interstitial lung disease (ILD), rapidly progressive ILD, and worse prognosis. Coexistence of anti-Ro52 and anti-SSA antibodies was further associated with a worse prognosis in anti-MDA5+ DM. In ASyS, anti-Ro52 antibodies were associated with pulmonary involvement but not with prognosis. In other MSA-defined subgroups, the clinical significance of anti-Ro52 antibodies was limited. CONCLUSION: Anti-Ro52 antibodies are highly prevalent in patients with IIMs, especially those with anti-MDA5 + DM and ASyS. Anti-Ro52 antibody testing may be a valuable tool for risk stratification and prognostic assessment in anti-MDA5 + DM and ASyS.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pan Q, Li S, Guo X, et al. Anti-Ro52 antibodies in idiopathic inflammatory myopathies: clinical significance across myositis-specific antibody-defined subgroups. Rheumatology (Oxford). 2026. PMID: 42647225. doi:10.1093/rheumatology/keag462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。